Non-ASH Meetings

Non-ASH Meetings

On-site interview with presenters at meetings and summits in the hematology/oncology arena

video

Ixazomib Benefit Persists Despite Prior Therapy in TOURMALINE-MM1 Subset Analysis

María-Victoria Mateos, MD, PhD, shares the results of a subset analysis of TOURMALINE-MM1, which showed that patients with prior exposure to proteasome inhibitors still...
video

Venetoclax Plus Hypomethylating Agents Leads to High Response Rates in Older Patients with AML

Daniel Pollyea, MD, shares results from an early, phase Ib study of venetoclax plus decitabine or azacitidine in older patients with treatment-naïve acute myeloid...
video

COMFORT: Five-Year Outcomes of Ruxolitinib in Patients With Myelofibrosis

Ruben A. Mesa, MD, provides an update on the COMFORT-1 trial, which found that ruxolitinib has durable efficacy and long-term safety in patients with...
video

CPX-351: A Potential Game-Changer for Older Patients With Newly Diagnosed Secondary AML?

Jeffrey Lancet, MD, discusses the findings from a phase III trial of CPX-351 versus 7+3 in older patients with high-risk, secondary acute myeloid leukemia
video

Study Finds Thrombosis Risk Changes Throughout Myeloma Disease Course

Brea Lipe, MD, discusses the risk of venous thromboembolism in patients with myeloma – and whether thromboprophylaxis guidelines need to be changed.
video

SL-401: An Encouraging Option for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm

Naveen Pemmaraju, MD, discusses early results from an ongoing trial of SL-401 in patients with the rare, aggressive malignancy blastic plasmacytoid dendritic cell neoplasm.
video

CASTOR Trial: Daratumumab Combination Doubles Response Rates in Myeloma Patients

Antonio Palumbo, MD, discusses the “unprecedented” results of the CASTOR Trial, a plenary, late-breaking abstract at ASCO 2016.
video

TOURMALINE-MM3 and 4: Ixazomib as Maintenance Therapy in Myeloma Patients

Sagar Lonial, MD, provides an update on TOURMALINE-MM3 and 4, which are looking at the role of ixazomib as maintenance therapy in patients with...
video

For Older AML Patients, Venetoclax With Low-Dose Cytarabine is Safe and “Promising”

Tara L. Lin, MD, shares the initial findings from a trial evaluating venetoclax with standard low-dose cytarabine in older patients with acute myeloid leukemia...
video

Bortezomib Leads to More Complete Remissions in Patients With High-Risk Follicular Lymphoma

Andrew M. Evens, DO, MSc, on the early results of ECOG-ACRIN E2408 trial, which found that adding bortezomib to standard bendamustine-rituximab treatment increases the...
Advertisement

Current Issue

June 2019, Volume 5, Issue 7

This issue features a debate about new treatment options for beta-thalassemia, a look at what’s driving skyrocketing drug prices in myeloma, and more.